Literature DB >> 26413978

Genetics of pancreatic neuroendocrine tumors: implications for the clinic.

Antonio Pea, Ralph H Hruban1, Laura D Wood1.   

Abstract

Pancreatic neuroendocrine tumors (PanNETs) are a common and deadly neoplasm of the pancreas. Although the importance of genetic alterations in PanNETs has been known for many years, recent comprehensive sequencing studies have greatly expanded our knowledge of neuroendocrine tumorigenesis in the pancreas. These studies have identified specific cellular processes that are altered in PanNETs, highlighted alterations with prognostic implications, and pointed to pathways for targeted therapies. In this review, we will discuss the genetic alterations that play a key role in PanNET tumorigenesis, with a specific focus on those alterations with the potential to change the way patients with these neoplasms are diagnosed and treated.

Entities:  

Keywords:  PanNET; genetics; islet cell tumor; mutation; pancreatic neuroendocrine tumor; sequencing

Mesh:

Substances:

Year:  2015        PMID: 26413978      PMCID: PMC4890468          DOI: 10.1586/17474124.2015.1092383

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  133 in total

Review 1.  Malignant endocrine tumor of the pancreas associated with von Recklinghausen's disease.

Authors:  Takashi Fujisawa; Tatsuya Osuga; Mitsuo Maeda; Norikazu Sakamoto; Tetsuo Maeda; Kazuhiko Sakaguchi; Yutaka Onishi; Masanori Toyoda; Hiroaki Maeda; Katsufumi Miyamoto; Nobuaki Kawaraya; Chosei Kusumoto; Takashi Nishigami
Journal:  J Gastroenterol       Date:  2002-01       Impact factor: 7.527

2.  Menin, a gene product responsible for multiple endocrine neoplasia type 1, interacts with the putative tumor metastasis suppressor nm23.

Authors:  N Ohkura; M Kishi; T Tsukada; K Yamaguchi
Journal:  Biochem Biophys Res Commun       Date:  2001-04-20       Impact factor: 3.575

3.  Deletion mapping of endocrine tumors localizes a second tumor suppressor gene on chromosome band 11q13.

Authors:  R Chakrabarti; E S Srivatsan; T F Wood; P J Eubanks; S A Ebrahimi; R A Gatti; E Passaro; M P Sawicki
Journal:  Genes Chromosomes Cancer       Date:  1998-06       Impact factor: 5.006

4.  Neurofibromatosis, phaeochromocytoma, and somatostatinoma.

Authors:  A M Cantor; C C Rigby; P R Beck; D Mangion
Journal:  Br Med J (Clin Res Ed)       Date:  1982-12-04

5.  The NF1 tumor suppressor critically regulates TSC2 and mTOR.

Authors:  Cory M Johannessen; Elizabeth E Reczek; Marianne F James; Hilde Brems; Eric Legius; Karen Cichowski
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-03       Impact factor: 11.205

6.  Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients.

Authors:  Daniela Speisky; Aurélie Duces; Ivan Bièche; Vinciane Rebours; Pascal Hammel; Alain Sauvanet; Stéphane Richard; Pierre Bedossa; Michel Vidaud; Arnaud Murat; Patricia Niccoli; Jean-Yves Scoazec; Philippe Ruszniewski; Anne Couvelard
Journal:  Clin Cancer Res       Date:  2012-03-29       Impact factor: 12.531

7.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

8.  Molecular parameters associated with insulinoma progression: chromosomal instability versus p53 and CK19 status.

Authors:  Y M H Jonkers; S M H Claessen; J A Veltman; A Geurts van Kessel; W N M Dinjens; B Skogseid; F C S Ramaekers; E-J M Speel
Journal:  Cytogenet Genome Res       Date:  2006       Impact factor: 1.636

9.  Loss of heterozygosity of chromosome 1q in gastrinomas: occurrence and prognostic significance.

Authors:  Yuan-Jia Chen; Alexander Vortmeyer; Zhengping Zhuang; Steve Huang; Robert T Jensen
Journal:  Cancer Res       Date:  2003-02-15       Impact factor: 12.701

10.  Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

Authors:  James C Yao; Alexandria T Phan; David Z Chang; Robert A Wolff; Kenneth Hess; Sanjay Gupta; Carmen Jacobs; Jeannette E Mares; Andrea N Landgraf; Asif Rashid; Funda Meric-Bernstam
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

View more
  9 in total

Review 1.  Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors.

Authors:  Sylvia L Asa; Stefano La Rosa; Olca Basturk; Volkan Adsay; Marianna Minnetti; Ashley B Grossman
Journal:  Endocr Pathol       Date:  2021-01-18       Impact factor: 3.943

Review 2.  Zebrafish patient avatars in cancer biology and precision cancer therapy.

Authors:  Maurizio Fazio; Julien Ablain; Yan Chuan; David M Langenau; Leonard I Zon
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

Review 3.  Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations.

Authors:  Gabriel Benyomo Mpilla; Philip Agop Philip; Bassel El-Rayes; Asfar Sohail Azmi
Journal:  World J Gastroenterol       Date:  2020-07-28       Impact factor: 5.742

4.  A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations.

Authors:  Przemysław Soczomski; Beata Jurecka-Lubieniecka; Aleksandra Krzywon; Alexander Jorge Cortez; Stanisław Zgliczynski; Natalia Rogozik; Małgorzata Oczko-Wojciechowska; Agnieszka Pawlaczek; Tomasz Bednarczuk; Barbara Jarzab
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-28       Impact factor: 5.555

5.  Long-term outcome after resection and thermal hepatic ablation of pancreatic neuroendocrine tumour liver metastases.

Authors:  J Kjaer; P Stålberg; J Crona; S Welin; P Hellman; A Thornell; O Norlen
Journal:  BJS Open       Date:  2021-07-06

6.  Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms.

Authors:  Alessandra Pulvirenti; Nitya Raj; Sara Cingarlini; Antonio Pea; Laura H Tang; Claudio Luchini; Joanne F Chou; Elisabetta Grego; Ioana Marinova; Marinela Capanu; Luca Landoni; Aldo Scarpa; Peter J Allen; David S Klimstra; Diane L Reidy-Lagunes
Journal:  Pancreas       Date:  2021-02-01       Impact factor: 3.243

Review 7.  Surgical and molecular pathology of pancreatic neoplasms.

Authors:  Wenzel M Hackeng; Ralph H Hruban; G Johan A Offerhaus; Lodewijk A A Brosens
Journal:  Diagn Pathol       Date:  2016-06-07       Impact factor: 2.644

8.  Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel.

Authors:  Ferga C Gleeson; Jesse S Voss; Benjamin R Kipp; Sarah E Kerr; John S Van Arnam; John R Mills; Cherisse A Marcou; Amber R Schneider; Zheng Jin Tu; Michael R Henry; Michael J Levy
Journal:  Oncotarget       Date:  2017-06-28

Review 9.  ALT Positivity in Human Cancers: Prevalence and Clinical Insights.

Authors:  Danny MacKenzie; Andrea K Watters; Julie T To; Melody W Young; Jonathan Muratori; Marni H Wilkoff; Rita G Abraham; Maria M Plummer; Dong Zhang
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.